Phase 2 N=30 ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
Diffuse Large B Cell Non-Hodgkin Lymphoma
Primary: Number of Participants With Dose Limiting Toxicity Events — 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Heart Failure Acute · Heart Failure，Congestive · Heart Failure; With Decompensation
Primary: Dyspnea — 1264; 1650 mmxh — p=0.18
Phase 4 N=40 Effect of Neuromuscular Blockade and Reversal on Breathing
Respiratory Insufficiency
Primary: Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response) — 0.66; 0.43; 0.54; 0.34 L/min/% desaturation
Phase 2 N=66 Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
Schizophrenia · Schizo-affective Disorder
Primary: Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone
Phase 2 N=3 A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Non-Alcoholic Steatohepatitis
Primary: Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 — NA; NA percentage
Phase 3 N=906 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menomune®…
Phase 2 N=99 Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion
Urinary Tract Infections · Catheter Infection · Catheter-Related Infections
Primary: Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI) — 7; 6 Participants
Phase 2 N=256 Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
Gastroesophageal Reflux
Primary: Percentage of Heartburn-Free 24-Hour Periods (Day and Night) During 4 Weeks of Treatment — 36.54; 36.69; 38.43 percentage of HBF 24-hour periods — p=0.7480
Phase 2 N=170 Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen
Chronic Hepatitis B
Primary: Difference in Percentage of Patients Between Treatment and Comparator Arm Reaching a ≥ 1log10 Decline of Quantitative HBsAg After 48 Weeks — 26; 1; 80; 53 Participants…
N/A N=1,457 PROPPER Prospective Registry of Outcomes With Penile Prosthesis
Erectile Dysfunction · Impotence
Primary: Number of Participants With Penile Prosthesis Overall Subject Satisfaction — 34; 34; 0; 0 Participants
N/A N=28 A Study on the Use of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome
Restless Legs Syndrome
Primary: The International Restless Legs Severity Scale — 17.3; 12.3; 16.9; 21.3 score on a scale
Phase 4 N=6 Study of the Effects of an Antidepressant Medication and Placebo on the Brain Functioning of Normal Subjects
Depression
Primary: Changes in Quantitative Electroencephalogram (qEEG) Prefrontal Cordance (PFC) Over Time (4 Weeks). — -0.54; -0.09; -0.09; -0.88 z-score — p=0.55
Phase 4 N=81 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
Phase 4 N=99 A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval
Pain
Primary: Median of Cumulative Pain Scores Up to 60 Minutes Post Procedure — 2; 2 score on a scale
N/A N=9 Bioactive Glass (Sol-gel) for Alveolar Bone Regeneration After Surgical Extraction
Bone Loss · Vertical Alveolar Bone Loss · Horizontal Alveolar Bone Loss
Primary: Change in Alveolar Crestal Bone Height — 0.32; 0.84; 1.59; 0.96 mm